lilly_building_with_american_flag_web

Lilly partners with Sitryx in $880m immunometabolism drug development deal

pharmafile | April 1, 2020 | News story | Research and Development |  Eli Lilly, Sitryx, partnership, pharma 

Eli Lilly and UK firm Sitryx have partnered up in a new drug development and commercialisation deal that could potentially be worth $880 million, it has been revealed.

The five-year deal gives Lilly the exclusive global rights to develop and market up to four of Sitryx’s preclinical compounds – including its two lead products – for the treatment of autoimmune diseases.

Within the partnership, Sitryx will handle drug discovery duties, while Lilly will fund and manage the developmental and commercial end of the partnership. To this end, Lilly will pay Sitryx $50 million up front, plus make a $10 million equity investment in the company. From there, Sitryx is eligible to receive up to $820 million in milestone payments, plus payments payable in royalties or on delivery of commercialisation targets “in the mid- to high-single digits”

Neil Weir, Chief Executive Officer of Sitryx, said his company was “excited to partner with Lilly, one of the global leaders in the field of immunology”, while Ajay Nirula, Lilly’s Vice President of immunology, commented: “As Lilly seeks to develop new and unique medicines for people suffering with autoimmune diseases, we are actively exploring a variety of scientific approaches both in our own labs and with external partners. Regulating the metabolism of immune cells is a promising approach to treating these diseases, and we look forward to working with the talented researchers at Sitryx to advance their novel immunometabolism targets.”

Advertisement

The deal will go ahead subject to customary closing conditions, the companies said.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Secarna Pharmaceuticals and Curie.Bio expand existing partnership

Secarna Pharmaceuticals has announced the expansion of the existing scientific and strategic collaboration agreement with …

The Gateway to Local Adoption Series

Latest content